|Written by Rob Goldman|
This week’s issue is sure to have something for everyone. Here is a sneak peek:
THE NEXT TOP PERFORMING GROUPS
We noted in last week’s edition of The Goldman Guide that due to unrest in the Middle East oil stocks were likely to rise. And rise they did, to the tune of around 3% for E&P (exploration and production) players and a tad higher for refiners. As we near the end of the quarter and the start of a new one, we are thinking big, as in big stocks and big movers in two sectors.
Looking at the big picture, big cap stocks have been the best performers of late as the Dow Jones Industrial Average has reached new highs. Conversely, small caps, particularly microcaps, have had a tougher time. Before we highlight why we think big will still be the place to be for the next couple of weeks, here is why small caps may lag behind and microcaps perform better than small cap:
1. Investors remain in neutral. That means they are more risk averse and when they buy stocks they tend to be bigger, less risky companies.
2. Volumes are still lower than earlier in the year and there is no indication they will rise.
3. As we touched upon in the latest edition of The 30-30 Report, the wide variance in Wall Street analysts estimates makes it difficult to discern value and true grow potential.
4. At 20x estimated 12-month forward EPS, small is not cheap. However, microcaps valuations are lower and more attractive, helping to bump up this group.
Big stocks are the recipients of the big rise in mutual fund inflows as well as the “neutral” behavioral approach of investors. Interestingly, when the AAII weekly investor sentiment survey’s Neutral category has a prolonged period at 40% or above, a big cap rally typically follows. With that in mind, here is why you need to buy oil stocks and biotechs.
Oil E&P Is The Place To Be
Four of the top 10 performing sectors of the past month are related to oil and gas in some way shape or form. Given the unrest in Iraq, and the current favorable valuations, despite the fact that some of companies are near year-highs, we believe that E&P stocks, which carry less risk than refiners, will build on the 3% rise last week. Plus, it is not uncommon that these stocks rise this time of year, anyway. As you might expect, we believe that ETFs may be the best way to play the trend. Below is a chart of four of the top oil and gas E&P ETFs. We think that PowerShares Dynamic Energy Expl and Prod (NYSE—PXE—$39.69) is the best play, since it carries the lowest P/E of the group but offers higher upside. PXE is the led line at the bottom of the four stock chart comparison.
By the way, be on the lookout for a new blog dedicated to ETFs beginning on Tuesday.
Two weeks ago we wrote extensively about the Russell index reconstitution and its effect on stocks. The preliminary list was published on June 13th, and the cutoff was the last day of May. Large block investors (Institutions/Money Managers) have been trying to get ahead of the event and make bets accordingly. It should be noted that Friday, June 27th is the date where the day where the final list is published and the reconstitution is final after the market close. The link below is the preliminary list from the Russell website.
Upon further review, it appears as if biotechs, whose performance as a sector has been nonexistent in recent months, dominates the Microcap Index’s preliminary list. This factor dovetails with our sentiment that microcaps present attractive opportunities as compared to their small cap brethren. Moreover, with a number of U.S.-based health care trying to take over European companies in order to have more favorable tax rates due to the new domicile, large, profitable biotechs are also good bets in the near term. Of course news of a Celgene (NASDAQ—CELG—$71.46) 2 for 1 stock split will keep these shares on the hot list.
In case you missed it, last week was a pretty good week for new GSCR research ideas.
On the sponsored research front, we initiated coverage of a small early stage e-cig company called ML Capital Group Inc. (OTCQB - MLCG) and it rose from just under $0.02 to roughly $0.06 in a matter of days before settling just under $0.05.
Our Sin Stock picks in last week’s Guide did well overall with Craft Brew Alliance (NASDAQ—BREW—$10.86) up 5% for the week.
The Uncensored Sensibility
If you are familiar with the current Washington Redskins nickname controversy, then this commentary is for you. We are starting our own bandwagon and submit that the following sport nicknames are offensive:
The Miami Hurricanes, Iowa State Cyclones, Tulsa Golden Hurricanes all remind me of terrible tragedies and the names appear to glorify them. The Carolina and Pittsburgh Panthers stole their name from a certain racially-based organization of a similar name. The New Jersey Devils, Duke Blue Devils, Arizona State Sun Devils....how can we root for the Devil to win anything?
Los Angeles Angels of Anaheim. What about all of those atheists living in Los Angeles or Anaheim? I feel so bad for them.
Oregon State Beavers....let’s skip this explanation...
University of South Florida Bulls...wouldn’t that make the women's teams' players Cows??? Where is NOW on this one?
The New Orleans Saints is very offensive. I will not support the Catholic Church until it supports abortion rights, gay marriage, rights for women's priests and not call them priestesses. And the Cleveland Browns? I don’t use UPS, I use FedEx so I don’t want to have to care what Brown did for me. I am sickened by the fact that the Purdue Boilermakers carries a nickname that supports underage drinking. The USC Trojans name is undemocratic. It is unfair to support one company like Trojan instead of, say, USC Lifestyles. I am watching Law and Order SVU as I write this and I can’t believe that the Nashville Predators get anyway with their nickname. How can anyone cheer or root for predators in this day and age? Providence Friars is a sad one. Everyone knows how obese we are getting and fried food is a major reason. The Connecticut Huskies (women's basketball team) is just embarrassing. Why not just call them BBWs?
Let’s not forget the red-headed leprechaun that is offensive to non-Notre Dame fans that are Catholic.
This week's piece is not in response to the latest move by the PTO regarding the Redskins patent. In fact, it is in honor of the memory of L.J. Locklear. He was the biggest Washington Redskins' fan I ever knew. I cannot even remember what his hair looked like because I can only remember him wearing one of his Washington Redskins Baseball Caps.
By the way, L.J. Locklear was a 100 % Lumbee Indian.
Be sure to pass this around and have a good week!
Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, With rare exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ. Goldman Small Cap Research members and contributors’ bios, certifications, and experience can be found on our website: www.goldmanresearch.com .
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces non-sponsored and sponsored (paid) investment research. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The Firm’s non-sponsored research publications category, Select Research, reflects the Firm’s internally generated stock ideas, along with economic, industry and market outlooks. In virtually all cases, stocks mentioned in Select Research offerings are listed on the NYSE or the NASDAQ. Publications in this category include the weekly newsletter The Goldman Guide, daily Market Monitor blogs, Special Reports, and premium products such as The 30-30 Report.
Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro cap research ideas that typically carry greater risks than those stocks covered in Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in company-specific Opportunity Research reports, updates and articles.
All information contained in this newsletter and in our reports were provided by the companies mentioned via news releases, filings, and their websites or generated from our own due diligence. Economic, market data and charts are provided by a variety of sources and are cited upon publication. Stock performance data is derived from Yahoo! Finance. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, other firms, or other financial news outlets. Goldman Small Cap Research relied solely upon information provided by companies through filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, blog, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.